Table 1 General data of 122 patients reported in case series/reports

Age (122)^a

Years

67 (14,86)^b

Sex

Male

87/122 (71.31%)

Female

35/122 (28.69%)

BMI (76)^a

kg/m²

23 (18.4,33.8)^b

HbA1c (101)^a

%

7.7 (5.4,14.4)^b

Region

China

105/122 (86.07%)

Japan

12/122 (9.64%)

India

1/122 (0.82%)

Finland

1/122 (0.82%)

Korea

1/122 (0.82%)

USA

2/122 (1.64%)

Indication for insulin (110)^a

T1DM

6/110 (5.45%)

T2DM

100/110 (90.91%)

LADA

3/110 (2.73%)

Pancreatic exocrine disease*

1/110 (0.91%)

Course of diabetes (118)^a

Years

10 (0.25,42)^b

Concomitant sulfhydryl drugs

Clopidogrel

1/122 (0.82%)

Concomitant autoimmune diseases

Grave’s diseases, Hashimoto's thyroiditis, sjogren syndrome, dermatitis eczematosa, psoriasis, poliomyelitis, rheumatoid arthritis

8/122 (6.56%)

Insulin dosage (100)^a

IU/day

26(8,95)^b

Duration of insulin use (86)^a

Months

24(0.13,288)^b

Insulin administration time before hypoglycemia (48)^a

Months

12(0.07,78)^b

Insulin types (115)^a

Bovine and porcine insulin (4)^a

4/115 (3.48%)

 Neutral protamine Hagedorn

4/4 (100%)

Insulin analogue (29)^a

29/115 (25.22%)

 Aspart

18/29 (62.07%)

 Glargine

10/29 (34.48%)

 Lispro

5/29 (17.24%)

 Detemir

5/29 (17.24%)

 Glulisine

1/29 (3.45%)

 No data

1/29 (3.45%)

Recombinant human insulin (19)^a

19/115 (16.52%)

 Short-acting insulin

14/19 (73.68%)

 Intermediate-acting insulin

11/19 (57.89%)

Premixed insulin (72)^a

72/115 (62.61%)

 Premixed human insulin

36/72 (50.00%)

  Novolin 30R

15/36 (41.67%)

  Humulin70/30

14/36 (38.89%)

  Novolin 50R

4/36 (11.11%)

  Gansulin30R

2/36 (5.56%)

  Gansulin50R

1/36 (2.78%)

Premixed insulin analogues

35/72 (48.61%)

 Aspart 30

32/35 (91.42%)

 Lispro 25

3/35 (8.57%)

Premixed animal-derived insulin

1/72 (1.39%)

 Wan Sulin 30R**

1/1 (100%)